Completed PHASE1 INTERVENTIONAL 1-arm NCT00226057

Efalizumab for Moderate to Severe Atopic Dermatitis

Efalizumab for Moderate to Severe Atopic Dermatitis - A Phase I Pilot Study in Adults

Sponsor: Oregon Health and Science University

Interventions Raptiva

Updated 5 times since 2017 Last updated: Dec 31, 2019 Started: Jun 30, 2005 Primary completion: Nov 30, 2005 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Dermatitis, Atopic, this trial is completed. The trial is conducted by Oregon Health and Science University and has accumulated 5 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Feb 2020 [monthly]

Completed PHASE1

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oregon Health and Science University

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.